Peripheral and Central Effects of Sertraline in Patients with Type 2 Diabetes Mellitus: Potential for Insulin Resistance Reduction
Disturbance of serotonergic processes of glucose homeostasis control, as well as eating behavior incorporates anxiety-depressive disorders and metabolic disorders, including obesity and type 2 diabetes. Dietary control, side effects of the chosen therapy can provoke a depressive disorder that will require pharmacological correction, and also reduces adherence to therapy, which prevents the achievement of target levels of glycaemia. In consistence with literature data, sertraline can help to better control weight and carbohydrate intake to achieve target glycaemia, improve the quality of life of patients, normalize eating behavior, and potentially reduce insulin resistance and apoptosis of pancreatic beta cells.